Competitive Outlook on Apoptosis in Oncology

Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells.

Scope of this report

In-depth competitive landscape assessment of the apoptopic market in oncology

Thorough review of utilized targets in apoptopic drug development

Thorough review of approved drugs

Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls

Research and analysis highlights

There are today over 190 apoptopic drugs in active development for the treatment of more than 40 different cancer indications. The top five pursued cancer indications are: breast cancer, leukemia, lung cancer, lymphoma and prostate cancer. A thorough target analysis of drugs in development reveals more than 130 candidate targets for triggering apoptosis in cancer cells.

Competitive forces are reviewed, showing market leaders, active players and changes in the competitive landscape. There are only one big pharma company represented among the top 10 players in apoptopic drug development in oncology. The acquisition of Idun Pharmaceutical in 2005 by Pfizer is a principal example of a further step in big pharma strategy to augment their internal research and development efforts with high-potential, externally sourced product candidates and technologies.

Key reasons to read this report

Understand the clinical and strategic challenges to the commercialization of apoptopic cancer drugs

Assess opportunities and risks for the continued development of apoptopic agents in five major cancer indications.

Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

Some of the almost 80 drugs included in this analysis

2-methoxyestradiol, AEE-788, aglycon protopanaxadiol, aplidine, ARQ-501, arsenic trioxide, BMS-387032, canertinib dihydrochloride, canfosfamide hydrochloride, combretastatin A-4 prodrug, idronoxil, indisulam, INGN-201, mapatumumab, motexafin gadolinium, oblimersen sodium, OGX-011, patupilone, PXD-101, rubitecan, tipifarnib, trabectedin etc.

Some of the more than 100 companies included in this analysis

Alfacell Corporation, AnorMED, Antigenics, Antisoma, ArQule, Array BioPharma, Attenuon, Bionovo, Bristol-Myers Squibb, Cephalon, ChemGenex Pharmaceuticals, Cougar Biotechnology, Cyclacel Group, Eisai, Eli Lilly, EntreMed, Erimos, Gardant, Gemin X Biotechnologies, Genta, Geron, GPC Biotech, Human Genome Sciences, Introgen Therapeutics, Johnson & Johnson, Lorus Therapeutics, Madaus, MethylGene, Novartis, Novogen, OncoGenex Technologies, OXiGENE, PanaGin, Pfizer, Pharmacyclics, PharmaMar, Seattle Genetics, SuperGen, Taxolog, Telik, TopoTarget, ViroTarg, ZymoGenetics etc.

December 2006 Pages 152
Table of Contents
Price: $2,999.00 / GBP1,499.50